Ovarian cancer trials in Spain

In Spain 89 Also abroad 795

89 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Where
Barcelona, Madrid
Age
18 years and over
People
156 worldwide
Run by
Context Therapeutics Inc.
See details and how to joinNCT06515613 · EU 2025-523968-20-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Where
Barcelona, Córdoba, Girona, L'Hospitalet de Llobregat, Madrid, Valencia
Age
18 years and over
People
770 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00
Phase 1/2Taking people
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Valencia
Age
18 years and over
People
605 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06843447 · EU 2024-514674-47-00
Phase 3Taking people
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Where
A Coruña, Barcelona, Córdoba, Girona, L'Hospitalet de Llobregat, Madrid, Valencia
Age
18 years and over
People
900 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00
Phase 1Taking people
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Where
Logrono, Madrid, Valencia
Age
18 years and over
People
150 worldwide
Run by
IDEAYA Biosciences
See details and how to joinNCT07503808 · EU 2026-526299-21-00
Phase 1Not yet taking people in Spain
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
Where
Barcelona, Madrid
Age
18 years and over
People
370 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00
Phase 3Taking people
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Where
Barcelona, Madrid, Málaga, Vigo
Age
18 years and over
People
420 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500
Phase 3Taking people
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Where
Barcelona, Palma de Mallorca, Patraix
Age
18 years and over
People
950 worldwide
Run by
AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
L'Hospitalet de Llobregat, Madrid, Sevilla
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Where
Barcelona, Las Palmas, Madrid, Málaga, Pamplona, Valencia
Age
18 years and over
People
200 worldwide
Run by
Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Where
Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo
Age
18 years and over
People
1,630 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Where
A Coruña, Badalona, Barcelona, Jaén, L'Hospitalet de Llobregat, Madrid, Majadahonda, Palma, Pamplona, Sabadell, Sevilla, Valencia
Age
18 years and over
People
688 worldwide
Run by
Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00
Phase 1/2Taking people
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Where
Barcelona, Girona, Huelva, Logrono, Madrid, Majadahonda, Pamplona, Pozuelo de Alarcón, Toledo
Age
18 years and over
People
334 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06303505 · EU 2024-511074-80-01
Phase 3Taking people
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Where
Barcelona, Córdoba, Donostia, Madrid, Murcia, Santiago De Compostela, Valencia
Age
18 years and over
People
270 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00
Phase 3Taking people
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
Where
Barcelona, Bilbao, Jaén, Madrid, Málaga, Vigo
Age
18 years and over
People
197 worldwide
Run by
K-Group Beta Inc.
See details and how to join2025-524641-27-00 · EU 2025-524641-27-00
Phase 2Taking people
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Where
Barcelona, Madrid, Majadahonda, Murcia, Pamplona, Valencia
Age
18 years and over
People
310 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT05128825 · EU 2022-502983-19-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Logrono
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
A Coruña, Barcelona, Córdoba, Donostia, Girona, L'Hospitalet de Llobregat, Madrid, Murcia, Palma, Pamplona, Sevilla, Valencia
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 1/2Taking people
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Where
Barcelona, Madrid
Age
18 years and over
People
248 worldwide
Run by
Terremoto Biosciences Inc.
See details and how to joinNCT07109726
Phase 2/3Taking people
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Where
Badalona, Barcelona, Jaén, Madrid, Pamplona, Valencia
Age
18 years and over
People
860 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Barcelona, Madrid, Málaga, Seville, Valencia
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 2Taking people
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Where
Alicante, Granada, Lugo, Madrid, Manresa, Reus, Sevilla, Valencia
Age
18 years and over
People
640 worldwide
Run by
North Eastern German Society of Gynaecological Oncology
See details and how to joinNCT05460000 · EU 2022-502559-69-01